BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 2966405)

  • 1. ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
    Furr BJ
    Prog Clin Biol Res; 1988; 260():13-26. PubMed ID: 2966405
    [No Abstract]   [Full Text] [Related]  

  • 2. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():69-76. PubMed ID: 2533159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen.
    Furr BJ; Valcaccia B; Curry B; Woodburn JR; Chesterson G; Tucker H
    J Endocrinol; 1987 Jun; 113(3):R7-9. PubMed ID: 3625091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The pharmacologic profile of flutamide].
    Racca S; Di Carlo F
    G Ital Chemioter; 1985; 32(1):7-11. PubMed ID: 2937678
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
    Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
    Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flutamide. Mechanism of action of a new nonsteroidal antiandrogen.
    Sufrin G; Coffey DS
    Invest Urol; 1976 May; 13(6):429-34. PubMed ID: 1270239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders.
    Battmann T; Branche C; Bouchoux F; Cerede E; Philibert D; Goubet F; Teutsch G; Gaillard-Kelly M
    J Steroid Biochem Mol Biol; 1998 Jan; 64(1-2):103-11. PubMed ID: 9569015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of cyproterone acetate and flutamide on blood calcium and bone structure].
    Manso Rodríguez G; Gutiérrez Cecchini B; Sala Blanco J; Hidalgo Balsera A
    Arch Esp Urol; 1986 Oct; 39(8):534-8. PubMed ID: 2950829
    [No Abstract]   [Full Text] [Related]  

  • 9. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
    Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
    Schröder FH
    Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
    Rennie PS; Bruchovsky N; Goldenberg SL; Lawson D; Fletcher T; Foekens JA
    J Urol; 1988 Jun; 139(6):1337-42. PubMed ID: 2967378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
    Steinsapir J; Mora G; Muldoon TG
    Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetics of antiandrogens in humans.
    Tremblay D; Dupront A; Meyer BH; Pottier J
    Prog Clin Biol Res; 1987; 243A():341-50. PubMed ID: 2958859
    [No Abstract]   [Full Text] [Related]  

  • 15. The place and the results of monotherapy.
    Bonnet P
    Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120
    [No Abstract]   [Full Text] [Related]  

  • 16. Biological aspects of antiandrogens.
    Neri RO; Peets EA
    J Steroid Biochem; 1975 Jun; 6(6):815-9. PubMed ID: 1177425
    [No Abstract]   [Full Text] [Related]  

  • 17. Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides.
    Tucker H; Crook JW; Chesterson GJ
    J Med Chem; 1988 May; 31(5):954-9. PubMed ID: 3361581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of a potent orally efficacious indole androgen receptor antagonist through in vivo screening.
    Lanter JC; Fiordeliso JJ; Jiang W; Allan GF; Lai MT; Linton O; Hahn do W; Lundeen SG; Sui Z
    Bioorg Med Chem Lett; 2007 Jan; 17(1):123-6. PubMed ID: 17071085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cyproterone acetate in comparison to flutamide on the ventral prostate of adult male castrated Copenhagen-Fisher rats and on Dunning R-3327 H tumors.
    Donn F; Becker H; Klosterhalfen H; Klein H
    Andrologia; 1989; 21(5):462-7. PubMed ID: 2530921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.